Want to see SGHT full AI Analyst Report?
SGHT Stock Chart & Stats
$5.12
$0.21(4.28%)
At close: 4:00 PM EDT
$5.12
$0.21(4.28%)
Day’s Range― - ―
52-Week Range$3.19 - $9.24
Previous Close$5.12
Volume72.72K
Average Volume (3M)150.61K
Market Cap
$286.20M
Enterprise Value$159.29
Total Cash (Recent Filing)$84.96M
Total Debt (Recent Filing)$41.76M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Aug 05, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding54,409,943
10 Day Avg. Volume244,568
30 Day Avg. Volume150,613
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)6.47
Price to Sales (P/S)5.35
P/FCF Ratio-13.82
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.40Price Target Upside64.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$86.08M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~86% gross margins indicate durable product-level economics driven by capital systems plus consumables. High margins provide pricing flexibility and margin conversion potential as revenue scales, supporting faster path to sustainable profitability if commercial growth and utilization trends continue.
Revenue Rebound And Guidance RaiseReturn to double-digit top-line growth and an upwardly revised full-year guide reflect improving market adoption and execution. A sustained revenue recovery across glaucoma and nascent dry-eye lines strengthens the investment case for scale-driven margin expansion and reduces execution risk over the medium term.
Improved Cash DynamicsMarked reduction in cash burn and a sizable cash runway improve financial resilience. If management converts guidance into sustained revenue growth while holding operating spend, the firm can reach positive operating cash flow without equity raises, preserving strategic optionality and supporting longer-term investment.
Bears Say
Persistent Losses And Cash ConsumptionDespite margin strength, consistent negative operating and free cash flow and multi-year net losses erode equity and constrain reinvestment capacity. Continued dependency on internal cash or external financing raises execution risk and could limit ability to fund commercial expansion or respond to competitive pressures over the medium term.
Dry Eye Market Early And ConcentratedInterventional Dry Eye shows rapid early growth but remains limited to select payers and few accounts. Broader commercial success requires additional payer wins and scaling a small sales organization, making revenue depend on successful reimbursement expansion and significant commercial investment over multiple quarters.
Legal Judgment UncertaintyA favorable patent judgment could materially boost cash and royalties, but appeals and parallel proceedings create timing and collectability risk. Reliance on contested legal proceeds to bridge cash needs or justify investments would be imprudent until judgments are final and payments are received.
Sight Sciences News
SGHT FAQ
What was Sight Sciences’s price range in the past 12 months?
Sight Sciences lowest stock price was $3.19 and its highest was $9.24 in the past 12 months.
What is Sight Sciences’s market cap?
Sight Sciences’s market cap is $286.20M.
When is Sight Sciences’s upcoming earnings report date?
Sight Sciences’s upcoming earnings report date is Aug 05, 2026 which is today.
How were Sight Sciences’s earnings last quarter?
Currently, no data Available
Is Sight Sciences overvalued?
According to Wall Street analysts Sight Sciences’s price is currently Undervalued.
Does Sight Sciences pay dividends?
Sight Sciences does not currently pay dividends.
What is Sight Sciences’s EPS estimate?
Sight Sciences’s EPS estimate is -0.18.
How many shares outstanding does Sight Sciences have?
Sight Sciences has 54,409,943 shares outstanding.
What happened to Sight Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sight Sciences?
Currently, no hedge funds are holding shares in SGHT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sight Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.40 (64.06% Upside)
$8.40 (64.06% Upside)
Blogger Sentiment
Bullish
SGHT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 29.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $444.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.41%
Trailing 12-Months
Company Description
Sight Sciences
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.
SGHT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive operational and financial picture: the company returned to double‑digit revenue growth, raised 2026 revenue guidance, showed meaningful early traction in the newly reimbursed Interventional Dry Eye market, sustained very strong gross margins, and demonstrated improved cash usage and lower adjusted operating expenses. Challenges remain—most notably continued net losses, concentrated payer coverage for TearCare, early penetration of the dry eye opportunity, and uncertainty around timing of cash from the legal judgment—but these risks were framed as manageable and addressable with targeted commercial investment. On balance the positive progress, guidance raise, margin strength, and improving cash dynamics outweigh the outstanding risks.View all SGHT earnings summariesSGHT Stock 12 Month Forecast
Average Price Target
$8.40
▲(64.06% Upside)
Technical Analysis
Ownership Overview
33.64% Insiders
5.81% Mutual Funds
0.13% Other Institutional Investors
52.98% Public Companies and
Individual Investors